Sapience Therapeutics Adds Biotech Veteran, Christian S. Schade, to Board of Directors

SCARSDALE, NY--(Marketwired - May 10, 2017) - Sapience Therapeutics, Inc., a biotechnology company focused on developing novel therapeutics to address difficult to treat oncology indications, announced today that it has appointed Christian S. Schade to its Board of Directors and Chair of its Audit Committee. Mr. Schade has more than 30 years of private and public pharmaceutical and biotechnology industry experience, and currently serves as the president and chief executive officer of Aprea Therapeutics, a privately held, clinical-stage biopharmaceutical company.

"Chris is a terrific addition to our Board," said Barry Kappel, Sapience's president and chief executive officer. "He brings decades of financial and business development experience to Sapience, which is a strong complement to the drug development expertise already possessed by the Board. I look forward to working with him as we develop our portfolio of ATF5-targeted therapies for the treatment of GBM and other oncology indications."

Mr. Schade commented, "I am excited to join Sapience's Board of Directors and work closely with this outstanding management and Board team. Sapience's innovative product candidates hold significant potential for the treatment of a number of cancers, and I am looking forward to contributing to the goal of advancing these important new treatments for patients who are underserved by current therapies."

In addition to his role with Aprea Therapeutics, Chris currently serves on the Board of Directors of Integra Life Sciences and Indivior PLC.

Prior to joining Aprea Therapeutics, Chris was chief executive officer of Novira Therapeutics Inc., a privately held biopharmaceutical company, until its acquisition by Johnson & Johnson in December 2015. Chris was previously executive vice president and chief financial officer of Omthera Pharmaceuticals, Inc., a specialty pharmaceutical company, prior to its sale in July 2013 to AstraZeneca. He was EVP and CFO at NRG Energy from March 2010 to September 2011. Chris joined Medarex Inc., in 2000 and helped it grow to become a leading pharmaceutical development company and, as senior vice president of administration and chief financial officer, played a lead role in the negotiations for Bristol-Myers Squibb Co.'s $2.4 billion acquisition of Medarex in September 2009 and the subsequent merger-integration process.

Prior to Medarex, Chris served as Managing Director and head of the European Corporate Funding Group at Merrill Lynch in London and also held various capital markets and corporate finance positions in New York and London for both Merrill Lynch and JP Morgan Chase & Co.

About Sapience Therapeutics

Sapience Therapeutics, Inc., is a privately held, preclinical stage biotechnology company focused on developing novel therapeutics for major unmet medical needs, particularly high mortality cancers. Our drug development program involves translating science into novel therapies, and our initial goal is to develop a first-in-class treatment for glioblastoma (GBM), which is the most severe and deadly form of brain cancer. For more information on Sapience Therapeutics, please visit www.sapiencetherapeutics.com.

Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements, and any statements other than statements of historical fact could be deemed to be forward-looking statements. These forward-looking statements may include, among other things, statements regarding future events that involve significant risks and uncertainties. These statements are based on management's current expectations, and actual results and future events may differ materially as a result of certain factors, including, without limitation, risks related to the application of the net proceeds from the offering to Sapience's product development objectives, our ability to obtain additional funds, and meet applicable regulatory standards and receive required regulatory approvals. These are forward-looking statements, which speak only as of the date of this press release. Sapience does not undertake any obligation to update any forward-looking statements as a result of new information, future events, changed assumptions or otherwise.